Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Danvatirsen - AstraZeneca/Ionis Pharmaceuticals

Next Previous
Drug Profile

Danvatirsen - AstraZeneca/Ionis Pharmaceuticals

Alternative Names: AZD-9150-sodium; AZD9150; Danvatirsen-sodium; IONIS-STAT3-2.5Rx; IONIS-STAT3Rx; ISIS-345794; ISIS-481464; ISIS-STAT3-2.5Rx; ISIS-STAT3Rx; STAT3Rx

Latest Information Update: 13 Aug 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company; Isis Pharmaceuticals
  • Developer Acerta Pharma; AstraZeneca; Flamingo Therapeutics; Ionis Pharmaceuticals; MedImmune; Montefiore Medical Center; National Cancer Institute (USA)
  • Class Antineoplastics; Antisense oligonucleotides
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Bladder cancer; Colorectal cancer; Head and neck cancer; Malignant ascites; Non-small cell lung cancer; Pancreatic cancer; Solid tumours
  • Phase I/II Liver cancer; Non-Hodgkin's lymphoma
  • Phase I Acute myeloid leukaemia; Myelodysplastic syndromes
  • No development reported Diffuse large B cell lymphoma

Most Recent Events

  • 08 Aug 2024 Phase-II clinical trials in Head and neck cancer (Combination therapy, Metastatic disease, Recurrent) in United Kingdom (IV) (NCT05814666)
  • 28 Mar 2024 AstraZeneca completes a phase Ib/II trial in Solid tumours (Combination therapy, Late-stage disease) in USA (IV) (NCT03421353)
  • 28 Mar 2024 AstraZeneca completes a phase Ib/II trial in Solid tumours (Combination therapy, Late-stage disease) in USA (SC) (NCT03421353)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top